466 related articles for article (PubMed ID: 28599901)
1. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.
Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; de Zeeuw D; Eckardt KU; McMurray JJV; Claggett B; Lewis EF; Pfeffer MA
Am J Kidney Dis; 2017 Oct; 70(4):522-531. PubMed ID: 28599901
[TBL] [Abstract][Full Text] [Related]
2. Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Grams ME; Yang W; Rebholz CM; Wang X; Porter AC; Inker LA; Horwitz E; Sondheimer JH; Hamm LL; He J; Weir MR; Jaar BG; Shafi T; Appel LJ; Hsu CY;
Am J Kidney Dis; 2017 Sep; 70(3):337-346. PubMed ID: 28366517
[TBL] [Abstract][Full Text] [Related]
3. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial.
Jhund PS; McMurray JJ; Chaturvedi N; Brunel P; Desai AS; Finn PV; Haffner SM; Solomon SD; Weinrauch LA; Claggett BL; Pfeffer MA
Eur Heart J; 2015 Sep; 36(36):2463-9. PubMed ID: 26188211
[TBL] [Abstract][Full Text] [Related]
4. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
5. Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR.
Massicotte-Azarniouch D; Kuwornu JP; Carrero JJ; Lam NN; Molnar AO; Zimmerman D; McCallum MK; Garg AX; Sood MM
Am J Kidney Dis; 2018 Feb; 71(2):191-199. PubMed ID: 29153994
[TBL] [Abstract][Full Text] [Related]
6. Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.
Lewis EF; Claggett B; Parfrey PS; Burdmann EA; McMurray JJ; Solomon SD; Levey AS; Ivanovich P; Eckardt KU; Kewalramani R; Toto R; Pfeffer MA
Am Heart J; 2015 Aug; 170(2):322-9. PubMed ID: 26299230
[TBL] [Abstract][Full Text] [Related]
7. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; Eckardt KU; McMurray JJV; Weinrauch LA; Liu J; Claggett B; Lewis EF; Pfeffer MA
Diabetes Obes Metab; 2019 May; 21(5):1199-1208. PubMed ID: 30672083
[TBL] [Abstract][Full Text] [Related]
8. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
Desai AS; Toto R; Jarolim P; Uno H; Eckardt KU; Kewalramani R; Levey AS; Lewis EF; McMurray JJ; Parving HH; Solomon SD; Pfeffer MA
Am J Kidney Dis; 2011 Nov; 58(5):717-28. PubMed ID: 21820220
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
[TBL] [Abstract][Full Text] [Related]
10. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease.
Sud M; Tangri N; Pintilie M; Levey AS; Naimark D
Circulation; 2014 Aug; 130(6):458-65. PubMed ID: 24899688
[TBL] [Abstract][Full Text] [Related]
11. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
Theilade S; Claggett B; Hansen TW; Skali H; Lewis EF; Solomon SD; Parving HH; Pfeffer M; McMurray JJ; Rossing P;
J Hum Hypertens; 2016 Jan; 30(1):46-52. PubMed ID: 25810068
[TBL] [Abstract][Full Text] [Related]
12. Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies.
Lash JP; Ricardo AC; Roy J; Deo R; Fischer M; Flack J; He J; Keane M; Lora C; Ojo A; Rahman M; Steigerwalt S; Tao K; Wolf M; Wright JT; Go AS;
Am J Kidney Dis; 2016 Oct; 68(4):545-553. PubMed ID: 27209443
[TBL] [Abstract][Full Text] [Related]
13. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
[TBL] [Abstract][Full Text] [Related]
14. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
Carrero JJ; Evans M; Szummer K; Spaak J; Lindhagen L; Edfors R; Stenvinkel P; Jacobson SH; Jernberg T
JAMA; 2014 Mar; 311(9):919-28. PubMed ID: 24595776
[TBL] [Abstract][Full Text] [Related]
15. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
16. Abrupt Decline in Kidney Function Before Initiating Hemodialysis and All-Cause Mortality: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Hsu RK; Chai B; Roy JA; Anderson AH; Bansal N; Feldman HI; Go AS; He J; Horwitz EJ; Kusek JW; Lash JP; Ojo A; Sondheimer JH; Townsend RR; Zhan M; Hsu CY;
Am J Kidney Dis; 2016 Aug; 68(2):193-202. PubMed ID: 26830447
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: A nationwide French observational study of hospitalized patients.
Ducluzeau PH; Fauchier G; Herbert J; Semaan C; Halimi JM; Angoulvant D; Fauchier L
Diabetes Metab; 2023 May; 49(3):101429. PubMed ID: 36736892
[TBL] [Abstract][Full Text] [Related]
18. Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study.
Hundemer GL; Knoll GA; Petrcich W; Hiremath S; Ruzicka M; Burns KD; Edwards C; Bugeja A; Rhodes E; Sood MM
Am J Kidney Dis; 2021 Feb; 77(2):178-189.e1. PubMed ID: 32920153
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998-2009.
Chang YT; Wu JL; Hsu CC; Wang JD; Sung JM
Diabetes Care; 2014; 37(1):277-85. PubMed ID: 23920086
[TBL] [Abstract][Full Text] [Related]
20. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention.
Parikh PB; Jeremias A; Naidu SS; Brener SJ; Lima F; Shlofmitz RA; Pappas T; Marzo KP; Gruberg L
Catheter Cardiovasc Interv; 2012 Sep; 80(3):352-7. PubMed ID: 22566286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
